A conceptual framework for clinical trials in SLE and other multisystem diseases

Abstract

Get full access to this article

View all access options for this article.

References

Feinstein AR . An additional basic science for clinical medicine: II. The limitations of randomized trials . Ann Intern Med 1983; 99: 544–550 .

Liang MH . Towards more informative pilot studies with new antirheumatic drugs . Agents Actions Suppl 1993; 44: 77–81 .

Anonymous . World Medical Association declaration of Helsinki Recommendations guiding physicians in biomedical research involving human subjects . JAMA 1997; 277: 925–926 .

Clark PI , Leaverton PE . Scientific and ethical issues in the use of placebo controls in clinical trials . Annu Rev Public Health 1994; 15: 19–38 .

Leber P . The placebo control in clinical trials (a view from the FDA) . Psychopharmacol Bull 1986; 22: 30–32 .

Kopec JA , Abrahamowicz M , Edaile JM . Randomized discontinuation trials: utility and efficiency . J Clin Epidemiol 1993; 46: 959–971 .

The Canadian Hydroxychloroquine Study Group . A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus . N Engl J Med 1991; 324: 150–154 .

Ware JH , Antman EM . Equivalence trials . N Engl J Med 1997; 337: 1159–1161 .

Karlson E , Liang MH . Prevalence of SLE: higher or lower? Lupus 1995; 4: 421–422 .

10.

Schwarzer AC , Arnold MH , Brooks PM . Combination therapy in rheumatoid arthritis . Baillieres Clin Rheumatol 1990; 4: 663–685 .

11.

Borigini MJ , Paulus HE . Combination therapy . Baillieres Clin Rheumatol 1995; 9: 689–710 .

12.

Felson DT , Anderson JJ , Meenan RT . The efficacy and toxicity of combination therapy in rheumatoid arthritis: A meta-analysis . Arthritis Rheumatol 1994; 37: 1487–1491 .

13.

Williams HJ , Egger MJ , Singer JZ et al. Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus . J Rheumatol 1994; 21: 1457–1462 .

14.

Hay EM , Bacon PA , Gordon C et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus . QJM 1993; 86: 447–458 .

15.

Liang MH , Socher SA , Larson MG , Schur PH . Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus . Arthritis Rheum 1989; 32: 1107–1118 .

16.

Bombardier C , Gladman DD , Urowitz MB et al. The Committee on Prognosis Studies in SLE. Derivation of the SLEDAI. A disease activity index for lupus patients . Arthritis Rheum 1992; 35: 630–640 .

17.

Bencivelli W , Vitali C , Isenberg DA et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. The European Consensus Study Group for Disease Activity in SLE . Clin Exp Rheumatol 1992; 10: 549–554 .

18.

Gladman D , Ginzler E , Goldsmith C et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus . Arthritis Rheum 1996; 39: 363–369 .

19.

Liang MH , Fortin PR . Response criteria for clinical trials in systemic lupus erythematosus . Lupus 1995; 4: 336–338 .

20.

Edwards JCW , Snaith MC , Isenberg DA . A double-blind controlled trial of methylprednisolone infusions in systemic lupus erythematosus using individualized outcome assessment . Ann Rheum Dis 1987; 46: 773–776 .

21.

Abrahamowicz M , Fortin PR , du Berger R et al. The relationship between disease activity and expert physicians decision to start major treatment in active systemic lupus erythematosus: a decision aid for development of entry criteria for clinical trials . J Rheumatol 1998; 25: 277–284 .

22.

Liang K-Y , Zeger SL . Longitudinal data analysis using generalized linear models . Biometrika 1986; 73: 13–22 .

23.

Cox DR . Regressions models and life tables (with discussion) . JR Statist Soc B 1972; 74: 187–220 .

24.

Côté R , Battista RN , Abrahamowicz M et al. Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. The Asymptomatic Cervical Bruit Study Group . Ann Intern Med 1995; 123: 649–655 .

25.

Senn S . Inherent difficulties with active control equivalence studies . Stat Med 1993; 12: 2367–2375 .

26.

Blackwelder WC , Chang MA . Sample size graphs for “proving the null hypothesis” . Control Clin Trials 1984; 5: 97–105 .

27.

Farrington CP , Manning G . Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk . Stat Med 1990; 9: 1447–1454 .

28.

Makuch R , Johnson M . Issues in planning and interpreting active control equivalence studies . J Clin Epidemiol 1989; 42: 503–511 .

29.

Roebruck P , Kühn A . Comparison of tests and sample size formulae for proving therapeutic equivalence based on the difference of binomial probabilities . Stat Med 1995; 14: 1583–1594 .

30.

Com-Nougue C , Rodary C , Patte C . How to establish equivalence when data are censored: a randomized trial of treatments for B nonHodgkin lymphoma . Stat Med 1993; 12: 1353–1364 .

31.

Abrahamowicz M , MacKenzie T , Esdaile JM . Time-dependent hazard ratio: modeling and hypothesis testing with application to lupus nephritis . J Am Statist Assoc 1996; 91: 1432–1439 .

32.

Gray RJ . Flexible methods for analyzing survival data using splines, with applications to breast cancer prognosis . J Am Statist Assoc 1992; 87: 942–951 .

33.

Hess KR . Assessing time-by-covariate interactions in proportional hazards regression models using cubic spline functions . Stat Med 1994; 13: 1045–1062 .